THE Therapeutic Goods
Administration has issued more
details of suspected adverse
reactions to Panvax,with a total of
1960 suspected side effects
reported as at 17 Sep - but only
190 related to Panvax Junior.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 07 Oct 10 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Oct 10
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).